MetaCap

NovoCure (NVCR) vs SI-BONE (SIBN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

SI-BONE (SIBN) has outperformed NovoCure (NVCR) over the past year, gaining 21.7% versus a loss of 10.4%. Over five years, SIBN leads with a +18.5% price change compared with -89.0% for NVCR. NovoCure is the larger company by market cap ($1.25 billion vs $1.07 billion), about 1.2 times the size, while SI-BONE is growing revenue faster (+20.2% vs +8.3%).

SI-BONE converts more of its revenue into profit, with a net margin of -9.4% versus -20.8%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NVCR-10.38%SIBN+21.69%
+73%+13%-46%
Nov 21, 20251 yearNov 20, 2026
NVCR-89.65%SIBN+11.72%
+42%-27%-97%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NVCR versus SIBN key metrics
MetricNVCRSIBN
Share price$10.71$23.73
Market cap$1.25B$1.07B
1-day change+0.19%-0.08%
YTD return-17.17%+20.33%
1-year return-10.38%+21.69%
5-year return-88.96%+18.53%
EPS (TTM)$-1.06$-0.31
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$655.35M$200.93M
Revenue growth (YoY)+8.28%+20.19%
Net income (latest FY)$-136.23M$-18.90M
Gross margin74.54%79.57%
Operating margin-23.47%-11.11%
Net margin-20.79%-9.41%
52-week high$21.45$25.92
52-week low$9.82$11.48
Distance from 52-week high-50.07%-8.45%
Analyst consensusbuystrong_buy
Avg. price target upside+144.07%+12.85%
Average volume1.51M709.79K
Shares outstanding116.92M45.11M
Employees1,605376
SectorHealth CareHealth Care
IndustryMedical/Dental InstrumentsMedical/Dental Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • SIBN has outperformed NVCR by 32.1 percentage points over the past year.
  • SI-BONE is more profitable, keeping -9.4 cents of every revenue dollar as net income versus -20.8 cents for NovoCure.
  • SI-BONE grew revenue faster in its latest fiscal year (+20.19% vs +8.28%).

About NovoCure

NVCR stock →

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax.

Health Care · Medical/Dental Instruments · 1,605 employees

About SI-BONE

SIBN stock →

SI-BONE, Inc., a medical device company, develops procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific applications in the United States and internationally. It offers a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products.

Health Care · Medical/Dental Instruments · 376 employees

NVCR vs SIBN FAQ

Which is bigger, NovoCure or SI-BONE?

NovoCure (NVCR) is larger, with a market capitalization of $1.25B compared with $1.07B for SI-BONE (SIBN).

Which stock has performed better over the past year, NVCR or SIBN?

SIBN returned +21.69% over the past 12 months, compared with -10.38% for NVCR (price return, excluding dividends). Past performance does not predict future results.

Are NovoCure and SI-BONE in the same industry?

Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.

More comparisons